المؤلفون: Jie Lou, Bingxin Gong, Yi Li, Yusheng Guo, Lin Li, Jing Wang, Weiwei Liu, Ziang You, Hongyong Zhang, Feng Pan, Bo Liang, Lian Yang, Guofeng Zhou

المصدر: Frontiers in Immunology; 2024, p01-14, 14p

مصطلحات موضوعية: BONE density, IMMUNE checkpoint inhibitors, IMMUNOTHERAPY, NON-small-cell lung carcinoma, IPILIMUMAB, PROPENSITY score matching, BIOMARKERS

المؤلفون: Chen, Xiu, Kou, Liqiu, Xie, Xiaolu, Su, Song, Li, Jun, Li, Yaling

المصدر: Immunology; May2024, Vol. 172 Issue 1, p21-45, 25p

مصطلحات موضوعية: IMMUNE checkpoint inhibitors, PROGNOSIS, HEPATOCELLULAR carcinoma, DRUG side effects, CANCER treatment, IPILIMUMAB

المؤلفون: Arai, Jun, Okumura, Akinori, Kato, Naoya, Ito, Kiyoaki

المصدر: Hepatology Research; May2024, Vol. 54 Issue 5, p420-428, 9p

مصطلحات موضوعية: MAJOR histocompatibility complex, HEPATOCELLULAR carcinoma, CELLULAR immunity, CHRONIC active hepatitis, KILLER cells, IPILIMUMAB

المؤلفون: Godfrey, Hannah, Jedlowski, Patrick, Thiede, Rebecca

المصدر: Australasian Journal of Dermatology; May2024, Vol. 65 Issue 3, p243-253, 11p

مصطلحات موضوعية: IMMUNE checkpoint inhibitors, FOOD chemistry, TOXIC epidermal necrolysis, DRUG eruptions, ANTINEOPLASTIC agents, IPILIMUMAB, STEVENS-Johnson Syndrome

الشركة/الكيان: UNITED States. Food & Drug Administration

المؤلفون: Nagao, Kae, Sakai, Arata, Tsumura, Hidetaka, Iemoto, Takao, Hirata, Yuichi, Hori, Hitomi, Ogisu, Kyohei, Kakuyama, Saori, Ikegawa, Takuya, Hirata, Tamaki, Ezaki, Takeshi, Furumatsu, Keisuke, Yamanaka, Kodai, Kato, Takao, Fujigaki, Seiji, Tanaka, Hidenori, Yagi, Yosuke, Tanaka, Takeshi, Kobayashi, Takashi, Masuda, Atsuhiro

المصدر: Journal of Gastroenterology; May2024, Vol. 59 Issue 5, p424-433, 10p

مصطلحات موضوعية: IMMUNE checkpoint inhibitors, PANCREATIC enzymes, IPILIMUMAB, IMMUNE checkpoint proteins, STEROID drugs

المؤلفون: Morita, Ayako, Ichihara, Eiki, Inoue, Koji, Fujiwara, Keiichi, Yokoyama, Toshihide, Harada, Daijiro, Ando, Chihiro, Kano, Hirohisa, Oda, Naohiro, Tamura, Tomoki, Ochi, Nobuaki, Kawai, Haruyuki, Inoue, Masaaki, Hara, Naofumi, Fujimoto, Nobukazu, Ichikawa, Hirohisa, Oze, Isao, Hotta, Katsuyuki, Maeda, Yoshinobu, Kiura, Katsuyuki

المصدر: International Journal of Cancer; May2024, Vol. 154 Issue 9, p1607-1615, 9p

مصطلحات موضوعية: NON-small-cell lung carcinoma, IMMUNE checkpoint inhibitors, EPIDERMAL growth factor receptors, PROBIOTICS, IPILIMUMAB, PEMETREXED

المؤلفون: Matsushita, Yuto, Kojima, Takahiro, Osawa, Takahiro, Sazuka, Tomokazu, Hatakeyama, Shingo, Goto, Keisuke, Numakura, Kazuyuki, Yamana, Kazutoshi, Kandori, Shuya, Fujita, Kazutoshi, Ueda, Kosuke, Tanaka, Hajime, Tomida, Ryotaro, Kurahashi, Toshifumi, Bando, Yukari, Nishiyama, Naotaka, Kimura, Takahiro, Yamashita, Shimpei, Kitamura, Hiroshi, Miyake, Hideaki

المصدر: International Journal of Urology; May2024, Vol. 31 Issue 5, p526-533, 8p

مصطلحات موضوعية: RENAL cell carcinoma, PROTEIN-tyrosine kinase inhibitors, IPILIMUMAB, ALBUMINS, TREATMENT effectiveness, METASTASIS

المؤلفون: Kött, Julian, Hoehne, Inka Lilott, Heidrich, Isabel, Zimmermann, Noah, Reese, Kim-Lea, Zell, Tim, Geidel, Glenn, Rünger, Alessandra, Schneider, Stefan W., Pantel, Klaus, Smit, Daniel J., Gebhardt, Christoffer

المصدر: Cancers; May2024, Vol. 16 Issue 9, p1737, 13p

مصطلحات موضوعية: MELANOMA prognosis, CHEMOKINES, MELANOMA, CANCER relapse, SURVIVAL rate, RESEARCH funding, IMMUNOTHERAPY, DESCRIPTIVE statistics, TUMOR markers, NIVOLUMAB, PROGRESSION-free survival, CONFIDENCE intervals, IPILIMUMAB, PROPORTIONAL hazards models

المؤلفون: Cui, Shuting, Sun, Xiaozhe, Gao, Junxi

المصدر: Expert Review of Anticancer Therapy; May2024, Vol. 24 Issue 5, p283-291, 9p

مصطلحات موضوعية: NIVOLUMAB, IPILIMUMAB, OVERALL survival, PROGRESSION-free survival, ODDS ratio, MELANOMA

المؤلفون: Han, Cheng-Long, Tian, Bao-Wen, Yan, Lun-Jie, Ding, Zi-Niu, Liu, Hui, Pan, Guo-Qiang, Zhang, Xiao, Mao, Xin-Chen, Tan, Si-Yu, Li, Rui-Zhe, Wang, Dong-Xu, Dong, Zhao-Ru, Yan, Yu-Chuan, Li, Tao

المصدر: Expert Review of Anticancer Therapy; May2024, Vol. 24 Issue 5, p303-312, 10p

مصطلحات موضوعية: IMMUNE checkpoint inhibitors, HEPATOCELLULAR carcinoma, IPILIMUMAB, ONCOLOGY